Global Renal Biomarkers Market Report and Forecast 2024-2032

Renal Biomarkers Market Size

The global renal biomarkers market was valued at USD 970.4 million in 2023 driven by the rising incidence of kidney diseases across the globe. The market is anticipated to grow at a CAGR of 7.65% during the forecast period 2024-2032 to reach a value of USD 1883.62 million by 2032. 

Renal Biomarkers Market Outlook

• Continuous research and development activities to explore new biomarkers for renal conditions are driving the market growth.

• The rising prevalence of chronic kidney diseases (CKD) is contributing to the increasing demand for novel treatments, propelling market demand.

• The efforts of research institutes and promising discoveries are bringing hope to the renal biomarker domain, boosting market value in the forecast period.

Renal Biomarkers Market Overview

Biomarkers are used to perform diagnoses and prognoses of medical conditions to curate and develop effective treatments for the medical condition. Biomarkers can be lipids, proteins, microRNAs, proteomic patterns, genes, metabolites, or cells present on a urinalysis. Renal biomarkers are supposed to be used to enhance diagnosis and treatment approaches for renal diseases.

Renal Biomarkers Market Growth Drivers

Rising Research Activities Poised to Bring Therapeutic Solutions

A new study published in May 2024 revealed that researchers discovered a novel biomarker in renal cell carcinoma subtypes. The cancer type is a diverse category with more than 20 known subtypes. The discovery is poised to enhance the ability to accurately diagnose many renal cell carcinoma subtypes, including some of the rarest subtypes. The enhanced diagnostic accuracy is expected to bring personalised treatments, improving patient outcomes. The discovery may trigger more researchers and key players to conduct additional research to explore more about the biomarker, anticipating market development.

Additionally, in January 2024, a group of researchers at MIT and Yale University School of Medicine discovered a compound originally developed as a potential cancer treatment that can allegedly treat autosomal dominant polycystic kidney disease (ADPKD). The drug exploits kidney cyst cells’ vulnerability to oxidative stress, a state of imbalance between damaging free radicals and beneficial antioxidants. The promising research is expected to bring innovative diagnostic approaches and treatments to the market, driving market growth. With a growing demand for biomarkers that can enable the development of targeted therapies and personalised treatments for patients, such research initiatives aimed at improving patient outcomes will propel market value in the coming years.

Renal Biomarkers Market Trends
 
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Renal Biomarkers Market Segmentation

Market Breakup by Biomarker Type

• Functional Biomarker

• Up-Regulated Proteins

• Others

Market Breakup by Technique

• Enzyme Linked Immunosorbent Assay

• Particle Enhanced Turbidimetric Immunoassay

• Calorimetric Assay

• Chemiluminescent Enzyme Immunoassay

• Liquid Chromatography Mass Spectrometry

Market Breakup by Application

• Diagnosis and Disease progression Monitoring

• Research Homecare

• Others

Market Breakup by End Users

• Diagnostic labs

• Outpatient Clinics

• Research Centers

• Hospitals

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Renal Biomarkers Market Share

Segmentation by Biomarker Type to Witness Substantial Growth

Based on biomarker type, the market is divided into functional biomarker, up-regulated proteins and others. These biomarkers play a critical role in diagnosing, monitoring, and managing kidney-related diseases. The segment dominance can be attributed to the continuous discoveries of new markers that allegedly enhance diagnostic accuracy and prognostic capabilities. The high reliance of healthcare professionals on the combination of biomarkers to enhance patient outcomes drives demand for personalised treatments, reducing the burden of renal diseases.

Diagnostic Labs are Expected to Dominate the Market Share by End Users

The market segment by end users includes diagnostic labs, outpatient clinics, research centers, hospitals, and others. Diagnostic labs are leading the market segment due to the rising number of biomarkers testing that takes place at diagnostic labs. It offers a wide range of biomarker tests that are used to diagnose various aspects of kidney diseases, contributing to increased market demand. Their expertise in handling complex diagnostic procedures ensures accurate results and makes them the preferred choice for renal biomarker testing, propelling market growth.

Renal Biomarkers Market Analysis by Region

Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Among these, North America dominates the market share due to the high prevalence of chronic kidney diseases (CKD) in the region. The CKD prevalence is probably high due to the rising incidence of other conditions such as diabetes and hypertension requiring effective, advanced diagnostic and monitoring tools. The presence of a robust healthcare infrastructure and the presence of prominent market players boost research, development, and innovation in the region, propelling market growth.

Leading players in the Renal Biomarkers Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Abbott Laboratories

It is an American multinational company that develops and sells medical devices and healthcare products. The company is a global leader in diagnostic solutions and offers advanced laboratory systems and point-of-care testing products. Their diagnostics division includes immunoassays, clinical chemistry, hematology, and molecular diagnostics.

BioPorto Diagnostics AS

Copenhagen-based BioPorto is an in-vitro diagnostics company specializing in antibodies and assay development. The company is focused on developing compelling products to address unmet medical needs and tests that can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

 
F.Hoffmann-La Roche AG

Commonly known as Roche, it is a Swiss multinational holding healthcare company operating in pharmaceuticals and diagnostics. It is the fifth-largest pharmaceutical company in the world by revenue specialising in providing treatments for cancer globally.

Siemens Healthineers AG

It is a German multinational company focused on providing innovative healthcare solutions through advanced technologies and services. The company offers a comprehensive range of diagnostic solutions, including clinical chemistry, immunoassays, hematology, and molecular diagnostics.

Thermo Fisher Scientific Inc.

It is a life science and clinical research company. Thermo Fischer develops diagnostic tests and instruments that are used in clinical and industrial settings, like immunoassays, microbiology, and molecular diagnostics.

Other key players in the market include Q² Solutions Company, BioMerieux SA, Sphingotec GmbH, Enzo Life Sciences Inc., and Randox Laboratories Ltd.

Key Highlights of the Report

Key Questions Answered in the Renal Biomarkers Market

• What was the global renal biomarkers market value in 2023? 
• What is the global renal biomarkers market forecast outlook for 2024-2032? 
• What are the regional markets covered in the EMR report? 
• What is market segmentation based on biomarker type?
• How is the market segmented based on technique?
• How is the market segmented based on application? 
• Who are the end-users in the market?
• What are the major factors aiding the global renal biomarkers market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which regional market is expected to lead the market share in the forecast period?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major global renal biomarkers market trends?
• Which application is expected to dominate the market? 
• Which biomarker type will dominate the market share?
• Which technique will lead the market?  
• Who are the key players involved in the global renal biomarkers market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?